Cargando…
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
OBJECTIVES: As the world transitions into a new era of the COVID‐19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. METHODS: We used 34...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916820/ https://www.ncbi.nlm.nih.gov/pubmed/33680466 http://dx.doi.org/10.1002/cti2.1258 |
_version_ | 1783657564375875584 |
---|---|
author | Rowntree, Louise C Chua, Brendon Y Nicholson, Suellen Koutsakos, Marios Hensen, Luca Douros, Celia Selva, Kevin Mordant, Francesca L Wong, Chinn Yi Habel, Jennifer R Zhang, Wuji Jia, Xiaoxiao Allen, Lily Doolan, Denise L Jackson, David C Wheatley, Adam K Kent, Stephen J Amanat, Fatima Krammer, Florian Subbarao, Kanta Cheng, Allen C Chung, Amy W Catton, Mike Nguyen, Thi HO van de Sandt, Carolien E Kedzierska, Katherine |
author_facet | Rowntree, Louise C Chua, Brendon Y Nicholson, Suellen Koutsakos, Marios Hensen, Luca Douros, Celia Selva, Kevin Mordant, Francesca L Wong, Chinn Yi Habel, Jennifer R Zhang, Wuji Jia, Xiaoxiao Allen, Lily Doolan, Denise L Jackson, David C Wheatley, Adam K Kent, Stephen J Amanat, Fatima Krammer, Florian Subbarao, Kanta Cheng, Allen C Chung, Amy W Catton, Mike Nguyen, Thi HO van de Sandt, Carolien E Kedzierska, Katherine |
author_sort | Rowntree, Louise C |
collection | PubMed |
description | OBJECTIVES: As the world transitions into a new era of the COVID‐19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. METHODS: We used 34 SARS‐CoV‐2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level‐3 containment. We correlated results from the sVNT with five additional commonly used SARS‐CoV‐2 serology techniques: the microneutralisation test (MNT), in‐house ELISAs, commercial Euroimmun‐ and Wantai‐based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen‐binding avidity, and high‐throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody‐secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers. RESULTS: Antibody data obtained with commercial ELISAs closely reflected results using in‐house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike‐specific IgG and IgA titres detected by both commercial and in‐house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh‐type 1 cell numbers correlated with spike and RBD‐specific IgG antibodies measured by ELISAs and sVNT. CONCLUSION: Our comprehensive analyses provide important insights into SARS‐CoV‐2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS‐CoV‐2‐specific humoral responses. |
format | Online Article Text |
id | pubmed-7916820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79168202021-03-05 Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features Rowntree, Louise C Chua, Brendon Y Nicholson, Suellen Koutsakos, Marios Hensen, Luca Douros, Celia Selva, Kevin Mordant, Francesca L Wong, Chinn Yi Habel, Jennifer R Zhang, Wuji Jia, Xiaoxiao Allen, Lily Doolan, Denise L Jackson, David C Wheatley, Adam K Kent, Stephen J Amanat, Fatima Krammer, Florian Subbarao, Kanta Cheng, Allen C Chung, Amy W Catton, Mike Nguyen, Thi HO van de Sandt, Carolien E Kedzierska, Katherine Clin Transl Immunology Original Article OBJECTIVES: As the world transitions into a new era of the COVID‐19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. METHODS: We used 34 SARS‐CoV‐2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level‐3 containment. We correlated results from the sVNT with five additional commonly used SARS‐CoV‐2 serology techniques: the microneutralisation test (MNT), in‐house ELISAs, commercial Euroimmun‐ and Wantai‐based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen‐binding avidity, and high‐throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody‐secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers. RESULTS: Antibody data obtained with commercial ELISAs closely reflected results using in‐house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike‐specific IgG and IgA titres detected by both commercial and in‐house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh‐type 1 cell numbers correlated with spike and RBD‐specific IgG antibodies measured by ELISAs and sVNT. CONCLUSION: Our comprehensive analyses provide important insights into SARS‐CoV‐2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS‐CoV‐2‐specific humoral responses. John Wiley and Sons Inc. 2021-02-28 /pmc/articles/PMC7916820/ /pubmed/33680466 http://dx.doi.org/10.1002/cti2.1258 Text en © 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Article Rowntree, Louise C Chua, Brendon Y Nicholson, Suellen Koutsakos, Marios Hensen, Luca Douros, Celia Selva, Kevin Mordant, Francesca L Wong, Chinn Yi Habel, Jennifer R Zhang, Wuji Jia, Xiaoxiao Allen, Lily Doolan, Denise L Jackson, David C Wheatley, Adam K Kent, Stephen J Amanat, Fatima Krammer, Florian Subbarao, Kanta Cheng, Allen C Chung, Amy W Catton, Mike Nguyen, Thi HO van de Sandt, Carolien E Kedzierska, Katherine Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features |
title | Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features |
title_full | Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features |
title_fullStr | Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features |
title_full_unstemmed | Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features |
title_short | Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features |
title_sort | robust correlations across six sars‐cov‐2 serology assays detecting distinct antibody features |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916820/ https://www.ncbi.nlm.nih.gov/pubmed/33680466 http://dx.doi.org/10.1002/cti2.1258 |
work_keys_str_mv | AT rowntreelouisec robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT chuabrendony robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT nicholsonsuellen robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT koutsakosmarios robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT hensenluca robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT douroscelia robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT selvakevin robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT mordantfrancescal robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT wongchinnyi robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT habeljenniferr robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT zhangwuji robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT jiaxiaoxiao robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT allenlily robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT doolandenisel robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT jacksondavidc robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT wheatleyadamk robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT kentstephenj robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT amanatfatima robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT krammerflorian robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT subbaraokanta robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT chengallenc robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT chungamyw robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT cattonmike robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT nguyenthiho robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT vandesandtcaroliene robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures AT kedzierskakatherine robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures |